key: cord-0957844-2o37lsja
authors: Hussain, Iqbal; Hussain, Afzal; Alajmi, Mohamed F.; Rehman, Md. Tabish; Amir, Samira
title: Impact of repurposed drugs on the symptomatic COVID-19 patients
date: 2020-12-07
journal: J Infect Public Health
DOI: 10.1016/j.jiph.2020.11.009
sha: e18bc325cead69c77fb8148b6d0707c4e90b9c04
doc_id: 957844
cord_uid: 2o37lsja

An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus capable of causing coronavirus disease 2019 (COVID-19), was declared as a global public health emergency on January 30, 2020, by the World Health Organization. In this devastating situation, precautionary measures, early diagnosis, and repurposed drugs appear to be timely and decisive factors by which to handle this problem until the discovery of an effective, dedicated vaccine or medicine is made. Currently, some researchers and clinicians have claimed evidence exists in favor of the use of some antimalarial drugs (chloroquine, hydroxychloroquine) antiviral drugs (remdesivir, favipiravir, lopinavir, ritonavir, umifenovir) vitamins, traditional Chinese medicines, and herbal medicines against SARS-CoV-2 infection. Based on the available literature, this review article sought to highlight the current understanding of the origin, transmission, diagnosis, precautionary measures, infection and drug action mechanisms, therapeutic role, and toxicities of targeted drugs for the prevention and cure of COVID‐19. This review may be useful for developing further strategies as a blueprint and understanding the mentioned drugs’ mechanisms to elucidate the possible target of action by which to successfully freeze the replication of the SARS-CoV-2 virus.

enzyme 2; ACE2) and receptor-binding domains of the virus' spikes could be a possible method for SARS-CoV-2 infection [17, 22, 23] . However, direct contact, respiratory droplets, and aerosols released by an infected person through coughing or sneezing facilitated the spread of SARS-CoV-2 in the community. The direct or indirect exposure of the eyes, mouth, and nose mucous membranes may also play a role in SARS-CoV-2 infection as the virus also remains in the air for a limited period of time and functions as an airborne pathogen [24] [25] [26] . Recently, the WHO announced that asymptomatic patients are not infectious [4] . In some cases, the digestive tract may have been the potential route of SARS-CoV-2 transmission rather than the respiratory tract, but further studies are required to confirm this possibility [27] . Breastfeeding mothers should also be studied regarding virus transmission because pregnant women have an increased chance of experiencing respiratory infections and extreme pneumonia [19, 22] . Precautionary measures such as quarantine, isolation, social distancing, and sanitization have been adopted to limit the escalation of the pandemic.

In the emergence of a virulent pandemic, the straightforward point-of-care (diagnosis), should be robust in terms of both handling and analysis. Until scientists and clinicians can contrive proper treatments for COVID-19 and they enter into daily practice, making an appropriate diagnosis is the only tool by which to help mitigate the current situation.

Currently, the use of molecular-based polymerase chain reaction (PCR) tests and serological assays, which detect the presence of antibodies in a blood sample, have been recommended by the WHO and United States (US) Centers for Disease Control and Prevention (CDC) [4, 28, 29] . Additionally, demographical; clinical; laboratory assessments J o u r n a l P r e -p r o o f including lymphopenia, prolonged prothrombin time, elevated lactate dehydrogenase, elevated alanine aminotransferase, elevated aspartate aminotransferase, elevated D-dimer, elevated neutrophils, eosinopenia, elevated C-reactive protein, and elevated troponin (including high-sensitivity troponin) [8, [30] [31] [32] [33] [34] [35] ; and radiological assessments such as chest X-ray or computed tomography imaging of COVID-19 patients can establish a line of action for the clinician to take regarding patient management. Moreover, other secondary infections/problems could be ruled out or, if present, the cure of the secondary infection/problem might be helpful to increase the immunity and lessen the traumatized condition of the patient.

The WHO and CDC have issued an advisory on the clinical and epidemiological findings of COVID-19 patients [4, 28, 29] . The preliminary diagnosis of a suspected case may include fever, respiratory symptoms, low lymphocyte count, travel history, direct contact with an infected patient, musculoskeletal pain, and diarrhea [36] . A molecular-based realtime reverse-transcriptase PCR (RT-PCR) test is currently being implemented as a standard method for COVID-19 patient diagnosis. In this test, the extracted viral RNA from oro-/nasopharyngeal (OP/NP) swab samples of the patient are input into the RT-PCR system, which is followed by the synthesis of cDNA using the reverse-transcriptase enzyme. The synthesized complementary DNA template accelerates the amplification of target sequences of the viral genome that could be highly homologous to SARS-CoV-2 [8, 37, 38] .

However, such RT-PCR test kits have many limitations, including timing and handling.

During RT-PCR, the concentration and quality of viral RNA affect the speed of targetsequence amplification of the viral genome, leading it to be considered only as a semiquantitative assay. Thus, the amplification rate can be used as a proxy for the sample viral J o u r n a l P r e -p r o o f load and false amplification can yield negative results, which could be a severe concern in the case of poor quality of the patient sample, a sample taken during an early stage of the disease, or poor experience among the analyzing personnel.

The suspected diagnosis of COVID-19 through RT-PCR requires analysis of an OP/NP swab, sputum, or bronchoalveolar lavage sample in the reference laboratory. The time between sample collection, transfer to the laboratory, and generation of the results take at least 24 to 72 hours, which seems to be time-consuming. At the same time, this process should become much faster with a streamlined approach enacted physically near to the patient (on-site) in urgent clinical scenarios. As such, the true prevalence of SARS-CoV-2 infection is currently unknown and the sensitivity of PCR to detect infection is also unclear.

Another tremendously used diagnosis method is serological testing [39] . In serological testing, an enzyme-linked immunosorbent assay (ELISA) is used detect the presence of immunoglobulins M and G (IgM and IgG) antibodies in whole blood, plasma, or a serum sample, which is a highly recommended approach relative to immunochromatography testing (Card test) due to its higher sensitivity and specificity, although the latter is convenient, inexpensive, and offers rapid turnover [40] . ELISA also boasts a quick turnover time; however, it may yield false-positive results due to the N (Nucleocapsid) proteins of SARS-CoV-2 [41, 42] . Cross-reactivity is expected with SARS-CoV-1 infection since there is 90% homology with the genetic sequence of SARS-CoV-2. Hence, ELISA kits should be explicitly developed to assess SARS-CoV-2 S proteins (transmembrane glycoprotein spikes) [43] . This is why the application of the serological test to SARS-CoV-2 is based on the choice of antigen and why the choice of an assay is less well-defined for SARS-CoV-2. Moreover, both serological and RT-PCR tests are complementary to each J o u r n a l P r e -p r o o f other and offer sustainable results according to their sensitivities at different stages of the infection. Therefore, it is recommended to combine both the modalities of diagnosis, which could be conducive for the enhanced sensitivity in the early detection and diagnosis of COVID-19 patients [44, 45] . Indeed, IgM-ELISA, in combination with RT-PCR, achieves a greater rate of detection than RT-PCR only at 98.6% versus 51.9%, respectively [42, 44, 45] . Additionally, lung radiography is a correlative diagnosis that provides potential shreds of evidence in the case of asymptomatic patients. Imaging modalities such as highresolution computed tomography could be quite useful in the diagnosis and observation of lung abnormalities (e.g., bilateral pulmonary parenchymal ground-glass and consolidative pulmonary opacities) in patients [8, 31, [46] [47] [48] [49] . The findings of abnormalities in computed tomography scans may be correlated with disease progression and prognosis. Based on the diagnosis, the patient's condition could be monitored and a line of action established for the delivery of further or intensive treatment or follow-up could be planned accordingly [50] .

Given the scarcity of proper medications of COVID-19, precautions and preventive measures are the key strategies by which to limit the escalation of the pandemic. Currently, the WHO and CDC have issued various advisories in support of preventing further spread of COVID-19 [29, 51] . The essential precautionary measures such as social distancing, quarantine of infected individuals, and hygiene of the environment are now in common practice for the prevention of SARS-CoV-2 spread. The measures described above have been adopted by human beings involved with COVID-19 patients or who face greater chances of infection such as local pharmacists, laboratory professionals, and skilled and J o u r n a l P r e -p r o o f unskilled human support in the industries. Additionally, health care professionals have been recommended to use personal protective equipment kits for their protection.

Meanwhile, environmental hygiene includes proper handwashing after touching surfaces in public places; covering the mouth and nose with the elbow or a tissue when you cough or sneeze; avoiding exposure to the public lavatory (e.g., wear a mask and gloves); carefully disposing of material containing nasal and oral secretions; and sanitizing standard tools, utensils, and frequently used surfaces regularly using disinfectants. Restraining from touching the face, eyes, nose, and mouth can curtail the chances of respiratory mucosal contamination [52, 53] . A blueprint for preventing the spread of SARS-CoV-2 infection is presented as follows:

 Avoid large events, mass gatherings, and close contact (less than six feet) with symptomatic individuals  Suspend travel to high-risk areas of serious illness  Use an alcohol-based hand sanitizer that contains at least 60% alcohol  Avoid sharing dishes, glasses, bedding, and other household items if you're sick 56] . Globally, government officials have been implementing considerable policies such as lockdown, social distancing, and selfquarantining to minimize public interaction, which helps to break the chain of transmission and results in a pause of COVID-19 spread in the community [57] . Additionally, immunity boosters are commonly recommended by clinicians to ensure a better response against the causative agent. The adequate intake of nutrients having vitamin C and D, fruits and vegetables, whole grains, nuts, and unsaturated fatty acids might play a role as immune boosters. Six to eight glasses of water daily can keep adults properly hydrated, which strengthens the physiological system of human beings and reduces fatigue and inflammation. All foodstuffs can be purchased through an online shop and delivered to the home to maintain social distancing [58, 59] .

For the treatment of any kind of disease, either the route of disease occurrence, mechanism of infection, or the action mechanism of the targeted drug has to be known in order to follow the line of action for treatment. Although the SARS-CoV-2 infection mechanism has already been explored, target drugs or vaccines remain under development due to the rapid mutation in the species [60] [61] [62] . SARS-CoV-2 is a positive-stranded RNA-enveloped virus with crown-shaped glycoproteins (S-protein) on their surface (as seen under the electron microscope); hence, it is referred to as a coronavirus (the Latin term for crown is corona). Initially, the receptor-binding domain of S-protein recognizes and binds to the host's ACE2 receptor. The transmembrane serine protease 2 on the surface of the host's cell receptors facilitates cross-species transmission, resulting in exposure of virus RNA and the translation of its RNA replicase to an RNA replicase-transcriptase complex, which J o u r n a l P r e -p r o o f supports the synthesis of encoded viral polyproteins inside the host's cells [60] [61] [62] . The viral RNA-dependent RNA polymerase synthesizes new RNA, which is encapsulated by structural proteins for the survival and infection of other host cells. Furthermore, this virulence migrates to other normal cells via exocytosis; consequently, the infection spreads inside other cells as illustrated in Figure 2 [63] [64] [65] . The spread of the infection across cells reaches the bronchial alveoli and extrapulmonary organs, causing pneumonia and affecting the function of the kidneys and other organs. Notably, ACE2 as the target receptor is not expressed in the respiratory system only but also in the kidneys and gastrointestinal tract, rendering these ideal target organs for SARS-CoV-2 invasion [60, 66] . Therefore, diagnosis and treatment in the early stage are essential for the prevention and control of SARS-CoV-2 infection. Moreover, the intensive review of the mechanism of infection is gaining attention as a way to understand existing drugs' pathways for mitigating viral spread as illustrated in Figure 2 and elucidated in the forthcoming sections.

Many drug regulatory authorities have taken intrusive steps to hold the market of unproven therapies to account. Capitalists are investing money in research focusing on developing the best options either for the cure or de-escalation of COVID-19. Currently, several therapies possibly able to be repurposed for COVID-19 are available, but nothing finite is approved so far. The exceptional spread and severity of COVID-19 have increased the demand for alternative medications to treat symptoms and control the virulence. Examples include CQ, HCQ, remdesivir, favipiravir, ribavirin, umifenovir, lopinavir/ritonavir, vitamins, antipyretics, and herbal medications (i.e., TCM) (see Figure 3 for more on antimalarial and antiviral drugs); these and other notable therapies are covered in Table 1 .

More than 300 clinical trials have been registered to date worldwide to explore possible therapeutics for COVID-19 [67] . Repositioning existing clinical trials remains the most valid strategy by which to expedite the discovery of new effective drugs. The existing pharmaceutical supply chain of formulation and distribution could similarly be of help in this situation. Combinations of different drugs might be more effective than monotherapy [68] . Currently, scientists and physicians are putting some evident and aforesaid alternative drugs on trial for combating COVID-19. However, the following drugs are those considered most viable at this time. Importantly, these are tentative options and should not be given in practice freely for the treatment or prevention of COVID-19.

Antimalarial drugs are known to possess in vitro and clinical antiviral activities against SARS-CoV-1 and SARS-CoV-2. CQ and its derivative, HCQ, are well-recognized drugs for the treatment of malaria and certain autoimmune diseases and have been gaining worldwide attention for the treatment of COVID-19 [5] . CQ and HCQ are synthetic drugs and usually developed from the bark of the cinchona plant family Rubiaceae [5] . There are several in vivo mechanisms of action for these drugs against different viruses (including SARS-COV) that have been proposed [69] ; however, in vivo data are still controversial [70, 71] . The administration of CQ increases the endosomal pH, which creates an adverse environment for the virus. CQ interferes with the glycosylation of SARS-CoV cellular receptors and substantially curtails the viral infection potential [72] . At higher lysosomal pH levels, the administration of CQ lowers cathepsin levels, resulting in the formation of autophagosome, which is responsible for SARS-CoV-2 spike-protein cleavage ( Figure 2 ).

CQ can also inhibit p38 mitogen-activated protein kinase (MAPK) via phosphorylation (activation) inside THP-1 cells as well as caspase-1 [73] . MAPK signaling activates virus cells to follow their replication cycle [74] alongside altering the virion assembly [72, 75] .

The mechanisms of action of CQ and HCQ are equal due to the structural resemblance of both molecules. Both molecules act as weak bases that can alter the pH of acidic intracellular organelles including endosomes/lysosomes, which are frequently required for membrane fusion. An extra hydroxyl group present in HCQ makes it less toxic, showing low permeability to the blood-retinal barrier and permitting rapid clearance from retinal pigment cells [76] . Additionally, in vitro testing indicated that HCQ sulfate is significantly superior (five days quicker) to the CQ phosphate in inhibiting SARS-CoV-2 [77, 78] .

Therefore, it is suggested that both agents are effective against SARS-CoV-1 and SARS-CoV-2 but with different degrees of potential [79, 80] . Furthermore, an in vitro study revealed that HCQ is found significantly more potent than CQ against SARS-CoV-2 (EC50 values: 0.72 and 5.47 μM, respectively) and the Taiwan CDC on March 26, 2020 declared HCQ to be an important anti-SARS-CoV-2 agent [11, 77, 81] . Consequently, the United States Food and Drug Administration also granted emergency authorization for HCQ to treat COVID-19 infection [82] . The combination of HCQ with azithromycin was studied in a nonrandomized clinical trial of HCQ alone or in combination with azithromycin (which is active in vitro against the Zika and Ebola viruses) of 20 patients, where 14 patients were treated with HCQ alone and six patients were treated with a combination of both drugs. A substantial reduction of the viral load in infected patients was observed in the combination therapy (HCQ and azithromycin) group; however, most of the patients who were treated with HCQ alone showed upper or lower respiratory-tract infections [83] . Gautret et al. J o u r n a l P r e -p r o o f conducted a clinical trial for the use of the above combination in the treatment of COVID-19 patients, where they observed positive results in severe cases [83] . The combination of HCQ and azithromycin is recommended for the treatment of COVID-19 patients with moderate to severe disease in many countries [84] ; however, there isn't enough evidence specifically concerning its efficacy and safety in the treatment of COVID-19 (ASHP).

Several ongoing clinical trials are investigating the efficacy of the therapeutic use and the safety of these medications against SARS-CoV-2 [77, 85] . HCQ and CQ can lead to fatal dysrhythmias, electrolyte disturbances, retinopathy, deficiency of glucose-6-phosphatase, and corrected QT interval prolongation. Patients with a history of allergy to HCQ or who are pregnant or breastfeeding are contraindicated from using this medication [83] .

Remdesivir (nucleotide analog GS-5734), a monophosphate prodrug, has been reported as a potential agent against several RNA viruses, including Ebola, SARS, and MERS, both in vitro and in nonhuman primates (1, 4) . It also exhibits SARS-CoV and MERS-CoV in vivo inhibition [72, 86, 87] . Notably, the nucleoside analog behavior of remdesivir facilitates the inhibition of RdRp, the protein complex of CoVs that controls RNA-based genome replication, thus potentially harming the viral genome replication process ( Figure 2 ). Once the host metabolizes remdesivir into active nucleoside triphosphate, the active metabolite develops the resistance toward adenosine triphosphate for its successful inclusion into the nascent RNA strand [88] . This inclusion of active substituents pauses RNA synthesis in an early stage and halts the growth of new RNA strands. While a proofreading tendency of CoVs that can detect and remove other nucleoside analogs and render them resistant against J o u r n a l P r e -p r o o f many of these drug agents exists, remdesivir outpaces this viral proofreading activity and generates antiviral activity [89] . Agostini et al. reported that a mutant murine hepatitis virus devoid of proofreading ability was abruptly sensitive to remdesivir [87] . However, the opposite is also possible; it can be assumed that mutations may also improve proofreading or increase the fidelity of the base-pairing process for remdesivir resistance [90] . However, some initial evidence suggests that remdesivir could have an additional mechanism of action that has not been ultimately discovered yet, which could be a new lead in favor of remdesivir still having partial antiviral activity despite viral mutations that enhance replication fidelity [87, 91, 92] . Recently, at a low micromolar concentration, remdesivir was found to be potentially active against SARS-CoV-2 in in vitro experiments and exhibited a high level of selectivity [72] . It has been reported to trigger a prompt reduction in fever and ensure greater improvement in clinical symptoms by the 12 th day of illness; at this point, the chest roentgenography of the patient under assessment showed relatively mild infiltrations and the rRT-PCR assay of an oropharyngeal swab was negative [93] .

Thereafter, remdesivir gained some attention globally due to its effect in the context of SARS-CoV-2 infection; however, more trials are needed to definitively prove its antiviral activity [94] . Some limited trials of remdesivir have yet to prove its efficacy [84, 95] .

Moreover, despite its strong in vitro potency against SARS-CoV-2, clinical success still must be proved [91, 93] and randomized controlled trials are still required to confirm its efficacy and safety [19] .

Favipiravir is one of the broad-spectrum nucleoside analogs antiviral drugs that has been approved against FLUAV in Japan (2014); this medication was found to act as a halting [98] . Clinically, it has been observed that favipiravir had some effect against SARS-CoV-2 infection in Chinese patients [99] . Randomized clinical trials are still ongoing to evaluate the efficacy of favipiravir plus interferon-α (ChiCTR2000029600) and favipiravir plus baloxavir marboxil (ChiCTR2000029544) [11] . In one study, patients with moderate and severe COVID-19 given favipiravir (n = 120) and umifenovir (n = 120) were compared; however, no significant differences were recorded between the groups. As such, further randomized controlled trials are needed to prove the efficacy of favipiravir as a possible COVID-19 treatment [61] .

Another possible synthetic nucleoside analog, ribavirin, which has shown potential antiviral activity against several viral infections including the hepatitis C virus, respiratory syncytial virus, some viral hemorrhagic fevers, and SARS in Hong Kong [100] [101] [102] , may work in the context of COVID-19. Ribavirin inhibits both RNA and DNA viruses, stopping their replication by suppressing the activity of inosine monophosphate dehydrogenase, which is required for guanosine triphosphate formation ( Figure 2 ). Ribavirin in combination with interferon-α2b was recorded to be effective against MERS-CoV in a rhesus macaque model [103] . Additionally, the regimen of lopinavir/ritonavir plus ribavirin was found to be effective against SARS-CoV in tissue cultures [104] . Therefore, ribavirin could be considered as a possible candidate therapy for the treatment of COVID-19 patients [19] . However, its undesirable adverse effect of reducing hemoglobin concentrations is harmful to patients in respiratory distress [105] . As such, currently, the high risk of toxicity J o u r n a l P r e -p r o o f due to ribavirin therapy outweighs its potential benefits as a possible treatment option for SARS-CoV-2 [106] . 

Lopinavir in combination with ritonavir is used for the treatment of human immunodeficiency virus (HIV) by affecting protein synthesis, a major step in HIV replication, and is well known as a protease-inhibitor therapy. Moreover, the combination of these drugs has been used for the treatment of SARS and MERS patients by ameliorating acute respiratory distress syndrome [104, 112, 113] . However, despite showing a good effect against MERS-CoV-infected marmosets, the significant impact of lopinavir in a tissue culture model is still controversial [114] . Lopinavir/ritonavir may have the possibility to bind with endopeptidase C30 of the SARS-CoV-2 protease due to its J o u r n a l P r e -p r o o f protease-inhibition tendency and could exhibit an antiviral effect in COVID-19 given this virus' resemblance to both the SARS-CoV-2 and SARS-CoV viruses (Figure 2 ) [115] .

Various clinical trials have tested the effect of the combination of lopinavir/ritonavir against COVID-19 but, unfortunately, promising results were not recorded [94, 104, 116, 117] . Meanwhile, the administration of lopinavir/ritonavir or interferon-β1b [112] . Despite the discouraging results, it is intriguing that at higher concentrations, lopinavir/ritonavir inhibits pulmonary SARS-CoV-2 replication and researchers have claimed that slightly fewer deaths were observed in the group receiving lopinavir/ritonavir in the late stage of SARS-CoV-2 infection as compared with in the standard-care group [112, 118] . In conclusion, lopinavir/ritonavir may not be effective for COVID-19 patients with mild pneumonia.

The above antimalarial (CQ and HCQ) and antiviral drugs (remdesivir) have emerged as promising treatment lead to the treatment of COVID-19. Moreover, synthetic recombinant interferon-α and interferon-β have also been considered in ongoing clinical trials because some evidence has been reported concerning the therapeutic benefit of synthetic recombinant interferon-α in SARS patients [119, 120] . Separately, oseltamivir is an antiviral drug approved for influenza A and B treatment and has been recommended for J o u r n a l P r e -p r o o f the treatment of COVID-19 patients in China, either alone or in combination with antibiotics and corticosteroids (e.g., hydrocortisone) [11, 31] . It is also under assessment in a clinical trial paired in multiple combinations with CQ and favipiravir ("Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID-19 : A Randomized Control Trial -Full-Text View -ClinicalTrials.gov," n.d.). The ASHP reviewed all of the abovementioned drugs and concluded that not enough evidence is available yet to prove the efficacy of any of them in the treatment of COVID-19 patients (ASHP website). Therefore, further evaluation of the efficacy and safety of the current antiviral drugs is still required [19] . The explanatory details about the clinical trials have been mention in the heading 7.

The adequate intake of vitamins could also be crucial in the treatment of COVID-19

patients. Many reports have suggested the importance of vitamins C and D in the prevention of lower respiratory-tract infections and suppression of viral replication rates, respectively [59, 122] . The provision of a high dose of vitamin C (2-10 g/day given over 8-10 hours) showed encouraging results in the treatment of 50 moderate to severe COVID-19 patients in China, triggering an improvement in the oxygenation index; notably, all of these patients were eventually cured and were discharged [123] . The simultaneous use of vitamin D was observed as worthy supplementation to reduce the chances of influenza [59] ; evidence that may support this activity is the finding of reduced 25-hydroxyvitamin D (25(OH) D) concentrations in COVID-19 patients. Consequently, it is suggested that people at risk of influenza and/or COVID-19 should take 10,000 IU/day of vitamin D3 for a few weeks to rapidly raise their 25(OH) D concentrations, followed by 5,000 IU/day.

This regimen is safe to deploy either orally or intravenously in COVID-19 patients [59, 124] .

The excessive use of nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen, and diclofenac has been associated with myocardial infarction, heart failure, and stroke, which is prevalent in acute respiratory-tract infection patients [125] [126] [127] .

Furthermore, NSAIDs can cause nephrotoxicity, which is more likely to appear among patients severely affected by COVID-19 [128, 129] . Hence, the role of NSAIDs in COVID-

COVID-19 that received wide publicity via international media coverage in France. In a case series report, four cases of children who took ibuprofen and experienced worsening symptoms of COVID-19 infection are detailed [130] . The reason for worsening symptoms was described by Fang et. al.: coronaviruses bind to ACE2 and ibuprofen administration can increase the bioavailability of ACE2, therefore potentiating the infectious processes of the former [131] . One of the best replacement for NSAIDs is acetaminophen, which has been suggested as a reasonable option until more evidence is collected [130] . In summary, the current epidemiologic evidence is not strong enough to infer a causal link between the harmful effect of ibuprofen and COVID-19. Evidence from mechanistic studies alone should not be used to make strong judgments against the use of ibuprofen. Still, it is recommended to use acetaminophen or ibuprofen with acetaminophen for fever reduction in a patient with COVID-19 [132] and the risk of adding ibuprofen should continue to be assessed against its benefits [133, 134] .

In most developing countries, given the scarcity of pharmaceuticals, about 80% of the population depends on traditional medicines for the treatment of various diseases [135] .

Indian and Chinese traditional herbs have a wide range of applications in the treatment of infectious and noninfectious diseases [98, 135] . Recently, TCM-mainly, Astragali Radix 

CQ and HCQ were found to be a blocker of virus cell entry by inhibiting autophagic flux and decreasing autophagosomelysosome fusion [144] . Gautret P, et.al. [83] reported the, nonrandomized clinical trial on 20 SARS-CoV-2-infected patients. The substantial results were found with reduction or disappearance of viral load using HCQ in COVID-19

J o u r n a l P r e -p r o o f patients. In this study, well know broad spectrum antibiotic azithromycin, were also given to the patients, and synergistic effect were observed to reinforce the antiviral effect of HCQ.

After these finding HCQ get tremendous recognition for the treatment and prophylaxis of COVID-19. The off-label use of HCQ in the treatment of COVID-19 were announced by several health agencies [145] . Unfortunately, U.S. Veterans Health Administration medical centers in April 2020 were reported no evidence that the use of HCQ, either with or without azithromycin, reduced the risk of mechanical ventilation in patients hospitalized with COVID-19. They performed a retrospective analysis of data from 368 patients hospitalized with confirmed SARS-CoV-2 infection and did not find any benefit of the HCQ even raised the concern about its safety. Increased rate of overall mortality was identified on the treatment of HCQ alone [146] . included. All patients were divided in to two group each group has 75 patients. One group were assigned to HCQ along with SOC and second group were on SOC alone. 200 mg HCQ was administrated daily for three days followed by a maintained dose of 800 mg daily for the remaining days up to 2 or 3 weeks for mild/moderate or severe patients, respectively. Main outcome indicated that HCQ administration did not result in a significantly higher probability of negative conversion than SOC alone [147] . because of positive results from small studies. However, the results of this study do not support its use in patients admitted to hospital with COVID-19 who require oxygen [148] .

In New York City, hospitalised COVID-19 patients were treated with HCQ, was not associated with either a greatly lowered or increased risk of the composite endpoint of intubation or death [149] . A randomized, double-blind, placebo-controlled trial across the United States and parts of Canada testing HCQ as post exposure prophylaxis. In this trial 821 adults who had household or occupational exposure to someone with asymptomatic confirmed COVID-19 were included. Within 4 days after exposure, the patients were randomly assigned to receive either placebo or HCQ (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 additional days). poor SARS-CoV-2-inhibition efficacy [11, 94] . NSAIDs can cause serious nephrotoxicity in severely affected COVID-19 patients [134] . The adequate use of all vitamins is a significant way to boost the immune system [159] .

The entire world continues to hope for the development of accurate treatments for COVID-19 in a timely fashion and hundreds of ongoing clinical trials aim to deescalate the pandemic. In this review, the potential roles of various existing drugs have been discussed and comparative information has been provided to help health care practitioners decide their effectiveness in the treatment of COVID-19. The mechanisms of these drugs have confirmed to promote the inhibition of SARS-CoV-2 virus replication, which suggests the ability of these medications to limit the viral load and prevent progression to severe disease [60, 78] . Because of the potential rapid mutation of the SARS-CoV-2 virus, drug resistance needs to be explored too [78] . Some TCM and macronutrients and micronutrients investigated to date in clinical trials of COVID-19 also need to be further evaluated either in combination with Western medicines or alone to estimate their overall efficacy against viral infections [160, 161] . More clinical studies are still required to develop standard protocols in COVID-19 treatment characterized by high efficacy and reduced toxicity.

These promising findings could constitute an impactful blueprint for the future [60, 111, 162] . 

Ongoing Clinical Trials for the Management of the COVID-19 Pandemic

Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy

COVID-19 situation update worldwide, as of

Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review

A Novel Coronavirus from Patients with Pneumonia in China

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Potential interventions for novel coronavirus in China: A systematic review

Old Weapon for New Enemy: Drug Repurposing for Treatment of Newly Emerging Viral Diseases

Treatment options for COVID-19: The reality and challenges

Controversial treatments: An updated understanding of the coronavirus disease 2019

?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F 2019-ncov%2Fcases-in-us.html

A new coronavirus associated with human respiratory disease in China

Corona Virus 101

The proximal origin of SARS-CoV-2

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

COVID-19): current status and future perspectives

A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19)

Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins

A Tale of Two Viruses: The Distinct Spike Glycoproteins of Feline Coronaviruses

Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus

2019-nCoV transmission through the ocular surface must not be ignored

Novel Wuhan (2019-nCoV) Coronavirus

Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection

The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single

An overview of coronaviruses including the SARS-2 coronavirus -Molecular biology, epidemiology and clinical implications

How Coronavirus Spreads | CDC n

Clinical Characteristics of Coronavirus Disease 2019 in China

Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Incidence, clinical characteristics and prognostic factor of patients with COVID-19: a systematic review and metaanalysis

Clinical and Laboratory Factors Predicting the Prognosis of Patients with COVID-19: An Analysis of 127 Patients

A simple laboratory parameter facilitates early identification of COVID-19 patients

Clinical characteristics of older patients infected with COVID-19: A descriptive study

Evidence based management guideline for the COVID-19 pandemic -Review article

Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients

Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients

Evaluation of Enzyme-Linked Immunoassay and Colloidal Gold-Immunochromatographic Assay Kit for Detection of Novel Coronavirus (SARS-Cov-2) Causing an Outbreak of Pneumonia (COVID-19)

Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures

Development and Clinical Application of A Rapid IgM-IgG Combined Antibody Test for SARS-CoV-2 Infection Diagnosis

COVID-19: From bench to bed side

Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)

Antibody against nucleocapsid protein predicts susceptibility to human coronavirus infection

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China

CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia

Asymptomatic novel coronavirus pneumonia patient outside Wuhan: The value of CT images in the course of the disease

Defining the Epidemiology of Covid-19 -Studies Needed

Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic

Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts

Global Pandemic Causing World-Wide Shutdown

World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19)

COVID-19: Emerging protective measures

Maintaining a healthy diet during the COVID-19 pandemic n

Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths

Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)

Structure, Function, and Evolution of Coronavirus Spike Proteins

Emerging coronaviruses: Genome structure, replication, and pathogenesis

An overview of their replication and pathogenesis

Coronavirus infection, ER stress, apoptosis and innate immunity

ACE2 Expression in Kidney and Testis May Cause Kidney and Testis Damage After 2019-nCoV Infection

• COVID-19 clinical trials worldwide by region

Clinical trials on drug repositioning for COVID-19 treatment

In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine

Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial

Paradoxical Effect of Chloroquine Treatment in Enhancing Chikungunya Virus Infection

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Gold Sodium Thiomalate and Chloroquine Inhibit Cytokine Production in Monocytic THP-1 Cells Through Distinct Transcriptional and Posttranslational Mechanisms

The Protein Tyrosine Kinase p56lck Is Required for Triggering NF-kappaB Activation Upon Interaction of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein gp120 With Cell Surface CD4 -PubMed n

Chloroquine for the 2019 novel coronavirus SARS-CoV-2

Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus

Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries

Chloroquine and hydroxychloroquine as available weapons to fight COVID-19

Design and Synthesis of Hydroxyferroquine Derivatives with Antimalarial and Antiviral Activities

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Pharmacotherapy in COVID-19; A narrative review for emergency providers

Toxicokinetics of hydroxychloroquine following a massive overdose

Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus

Learning from the Past: Possible Urgent

Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV

Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase

First Case of 2019 Novel Coronavirus in the United States

Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan

Community Transmitted Case of Severe Acute Respiratory Distress Syndrome due to SARS CoV2 in the United States

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase

Discovery and development of safe-in-man broad-spectrum antiviral agents

COVID-19: A promising cure for the global panic

Favipiravir shows good clinical efficacy in treating COVID-19: official -Xinhua | English

Managing SARS amidst Uncertainty

Prolonged disturbances of in vitro cytokine production in patients with severe acute respiratory syndrome (SARS) treated with ribavirin and steroids

Coronavirus as a possible cause of severe acute respiratory syndrome

Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoVinfected rhesus macaques

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings

Compounds with Therapeutic Potential against Novel Respiratory

Mount Sinai Health System Treatment Guidelines for SARS-CoV-2 Infection

The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection -Full Text View -ClinicalTrials

Antiviral Activity of Arbidol and Its Derivatives Against the Pathogen of Severe Acute Respiratory Syndrome in the Cell Cultures

Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment

Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics

Therapeutic management of patients with COVID-19: a systematic review

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Coronaviruses -drug discovery and therapeutic options

Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset

Molecular modeling evaluation of the binding of ritonavir, lopinavir and darunavir to severe acute respiratory syndrome coronavirus 2 proteases

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Treatment of Severe Acute Respiratory Syndrome With Lopinavir/Ritonavir: A Multicentre Retrospective Matched Cohort Study -PubMed n

Covid-19 -The Search for Effective Therapy

Interferon Alfacon-1 Plus Corticosteroids in Severe Acute Respiratory Syndrome

Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID-19 : A Randomized Control Trial

Can early and high intravenous dose of vitamin C prevent and treat coronavirus disease 2019 (COVID-19

Expert Coronary Disease Comprehensive Treatment Consensus n

High-Dose Vitamin C (PDQ®)-Health Professional Version -National Cancer Institute n

Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials

Risk of stroke associated with use of nonsteroidal anti-inflammatory drugs during acute respiratory infection episode

Acute Respiratory Infection and Use of Nonsteroidal Anti-Inflammatory Drugs on Risk of Acute Myocardial Infarction: A Nationwide Case-Crossover Study

The Invisible Threat of Nonsteroidal Anti-inflammatory Drugs for Kidneys. Front Pediatr

Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis

Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?

WHO clarifies guidance on ibuprofen, says there's no evidence it can worsen COVID-19 | CBC News n

Safety of Ibuprofen in Patients With COVID-19

Non-steroidal anti-inflammatory drugs and covid-19

Pay attention to situation of SARS-CoV-2 and TCM advantages in treatment of novel coronavirus infection

Treatment of COVID-19: old tricks for new challenges

Can Chinese Medicine Be Used for Prevention of Corona Virus Disease 2019 (COVID-19)? A Review of Historical Classics, Research Evidence and Current Prevention Programs

Effect of Root Extracts of Medicinal Herb Glycyrrhiza glabra on HSP90 Gene Expression and Apoptosis in the HT-29 Colon Cancer Cell Line

Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle

A review on antiviral activity of the Himalayan medicinal plants traditionally used to treat bronchitis and related symptoms

Screening of Indonesian plant extracts for anti-human immunodeficiency virus-type 1 (HIV-1) activity

Evaluation of Ocimum sanctum and Tinospora cordifolia as Probable HIV-Protease inhibitors | Request PDF n.d

PDF) HIV-1 reverse transcriptase inhibition by Vitex negundo L. leaf extract and quantification of flavonoids in relation to anti-HIV activity n

Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion

Emergency use authorization, hydroxychloroquine sulfate health care provider fact sheet. U.S. Food and Drug Administration

Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19

Hydroxychloroquine in mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial

Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

Compassionate Use of Remdesivir for Patients with Severe Covid-19

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Remdesivir for the Treatment of Covid-19 -Preliminary Report

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Ocular Toxicity of Hydroxychloroquine -PubMed n.d

Hospital pharmacists' pharmaceutical care for hospitalized patients with COVID-19: Recommendations and guidance from clinical experience

Vitamin C deployed in big doses to help treat coronavirus patients | South China Morning Post n

Diagnosis and treatment of novel coronavirus pneumonia based on the theory of traditional Chinese medicine

A Review of Micronutrients and the Immune System-Working in Harmony to Reduce the Risk of Infection

Study of High-Dose Chloroquine For COVID-19 Stopped Early Due to Patient Deaths n

chloroquine-stopped-early-due-to-safety-concerns

Medicines against Coronavirus -research overview | vfa n

Acknowledgment: "The authors acknowledge the generous support received from the

J o u r n a l P r e -p r o o f